PCSK9
内体
高脂血症
基因沉默
内吞循环
炎症
纳米载体
细胞生物学
前蛋白转化酶
化学
核酸
微泡
细胞外
全身给药
载脂蛋白B
细胞外小泡
低密度脂蛋白受体
遗传增强
内吞作用
胆固醇
前蛋白转化酶类
癌症研究
全身炎症
生物化学
并列信号
可欣
RNA干扰
药理学
脂质体
作者
Qinyu Li,Xiang Lü,Qing Liu,Hongyu Liu,Yangyuan Ye,Ye Cui,Chang Liu,Gulixian Aili,Yi Liu,Hao Feng,Anqi Xu,Li Liang,Miaorong Yu,Di Nie,Yong Gan
摘要
Hyperlipidemia is a systemic metabolic disorder closely associated with chronic inflammation. Effective management requires integrated strategies that simultaneously lower lipid level and attenuate inflammation. Nucleic acid therapeutics, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) siRNA, represent a breakthrough in lipid-lowering therapy. However, they either lack direct anti-inflammatory effects (GalNAc-siRNA) or are prone to triggering unintended inflammatory responses themselves such as lipid nanoparticles (LNPs). Milk-derived extracellular vesicles (MDEs) emerge as naturally anti-inflammatory nanocarriers that suppress key pro-inflammatory cytokines by 30.0%-96.5% in vitro. However, MDEs predominantly undergo endocytic trafficking with substantial endosomal/lysosomal sequestration, which can limit productive cytosolic siRNA delivery. To address this, we developed engineered MDEs by incorporating 30.0% (w/w) probiotic-derived glycolipids into their membranes to facilitate early endosomal escape. When loaded with PCSK9 siRNA, the engineered MDEs achieved a remarkable silencing efficiency of 90.2 ± 0.2%, significantly outperforming both unmodified MDEs and conventional LNPs. In hyperlipidemic mice, systemic administration of engineered MDEs improved serum lipid profiles, reduced lipid accumulation and systemic inflammation, and showed a favorable safety profile under the conditions examined. Collectively, this work provides a promising nucleic acid delivery platform based on engineered MDEs for enhanced hyperlipidemia therapy through simultaneous lipid-lowering and anti-inflammatory effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI